AI-generated Recursion Pharmaceuticals (RXRX) stock analysis report, as of Nov 3, 2026. See RXRX business overview, financial statement overview, technical analysis and price target.
Do you use Git daily? Are you developing frontends with Vite? On November 10, 2026, security updates were released for both ...
Git security updates fix six flaws, including one that lets malicious repositories execute attacker code during recursive cloning.
Salt Lake City, UT, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering ...
Anthropic has warned that it may be approaching a stage in artificial intelligence development where AI systems significantly ...
Good morning, everyone, and thank you for joining Recursion's Third Quarter Earnings Call. We're hosting earnings live from ...
Recursion said it expects to launch its first registrational trial in the second half of this year for its lead candidate REC-4881 based on talks with the FDA, after the oral familial adenomatous ...
Recursion’s Q3 2026 earnings call highlighted REC-4881 FAP data, REC-1245 tumor responses, $749 million in pro forma cash and ...
Tencent's Hunyuan Research Agent version 2.0 made its debut Monday, claiming to have crossed a threshold that has defined the ambition of AI-for-science research for a decade: instead of solving ...
Do you ever get lost in your head while trying to follow recursive problems?In the autumn of 2025, a junior colleague asked ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results